What is the current stock price of Petros Pharmaceuticals, Inc. (PTPI)?

As of the latest market data, Petros Pharmaceuticals, Inc. (PTPI) is trading at $0.01. The stock has seen a loss of -16.67% today.

Does Petros Pharmaceuticals, Inc. (PTPI) pay a dividend?

Based on current data, Petros Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Petros Pharmaceuticals, Inc.?

The current market capitalization of Petros Pharmaceuticals, Inc. (PTPI) is approximately unavailable.

PTPI

Petros Pharmaceuticals, Inc.·Healthcare

0.01

16.667%(−0.00)

Market Closed

0.01

28.000%(+0.00)

After Hours

Last Updated: — ET

52W L: $0.0052W H: $2.63

PTPI NEWS

defenseworld.net

Mar 21

Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)

Cuprina Holdings (Cayman) (NASDAQ: CUPR - Get Free Report) and Petros Pharmaceuticals (NASDAQ: PTPI - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Institutional and Insider Ownership 12.3% of

Company Profile

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2020-12-02

Beta

1.66

Websitewww.petrospharma.com↗